NV354, Potential Therapy for Mitochondrial Diseases, Shows Promise in Preclinical Studies
News
NeuroVive Pharmaceutical’s therapeutic candidate NV354 for mitochondrial diseases, such as Leigh syndrome, was able to restore the body’s own energy substrate — succinate — in an in vivo model of ... Read more